Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Summary of Components of Marketable Securities

The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (in thousands) (see fair value of financial instruments):

	As of September 30, 2022
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. government obligations	$	1,448	$	-	$	(93	)	$	1,355
Corporate obligations		2,342		129		(148	)		2,323
	$	3,790	$	129	$	(241	)	$	3,678

	As of December 31, 2021
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value
U.S. government obligations	$	650	$	17	$	-		$	667
Corporate obligations		8,304		-		(192	)		8,112
	$	8,954	$	17	$	(192	)	$	8,779

Schedule of Accounts Receivable Net

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

	September 30, 2022			December 31, 2021
Trade accounts receivable	$	38,231		$	18,520
Unbilled accounts receivable		6,031			23,089
		44,262			41,609
Less allowances		(6,430	)		(3,901	)
Total accounts receivable	$	37,832		$	37,708

Schedule of Components of Inventory

At September 30, 2022 and December 31, 2021, the components of inventory are as follows (in thousands):

	September 30, 2022			December 31, 2021
Diagnostic services testing material	$	2,271		$	2,989
Raw materials		1,904			1,514
Work in process		609			260
Finished goods		383			272
Inventory	$	5,167		$	5,035
Inventory valuation reserve		(255	)		(435	)
Inventory, net	$	4,912		$	4,600

Schedule of Fair Value of Financial Instruments

	As of September 30, 2022
	Level 1		Level 2		Level 3		Total
U.S. government obligations	$	-	$	1,355	$	-	$	1,355
Corporate obligations		-		2,323		-		2,323
	$	-	$	3,678	$	-	$	3,678

	As of December 31, 2021
	Level 1		Level 2		Level 3		Total
U.S. government obligations	$	-	$	667	$	-	$	667
Corporate obligations		-		8,112		-		8,112
Marketable equity securities		76		-		-		76
	$	76	$	8,779	$	-	$	8,855

Schedule of Deferred Revenue

The following table disaggregates our deferred revenue by recognition period (in thousands):

Recognition Period	September 30, 2022		December 31, 2021
0-12 Months	$	2,958	$	2,034
13-24 Months		626		530
Over 24 Months		301		375
Total	$	3,885	$	2,939

Schedule of Disaggregation by Revenue

The following table disaggregates the Company’s revenue by revenue source for the three and nine months ended September 30, 2022 and 2021 (in thousands):

	For the three months ended				For the nine months ended
Revenue by Customer Type	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021
Diagnostic services	$	20,542	$	7,142	$	91,613	$	27,416
Contract manufacturing		2,749		1,120		5,662		4,069
Retail and others		357		1,210		1,369		2,400
Genomic products and services		552		-		2,180		-
Total revenue, net	$	24,200	$	9,472	$	100,824	$	33,885